Table 4 Selected studies that provide data for the utilization of HCC surveillance in cohorts with chronic hepatitis B
From: Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Study | Study period | Location | Study setting | Study population | Utilization of surveillance |
|---|---|---|---|---|---|
Clinical cohorts with data verified by chart review | |||||
Wang et al.38 | 1996–2013 | USA | 4 clinics | 1,329 with chronic HBV (164 with cirrhosis) | 38.4% of patients with cirrhosis had optimal HCC surveillance versus 23.4% of patients who did not have cirrhosis but met AASLD criteria for surveillance |
Administrative data base studies | |||||
Goldberg et al.195 | 2006–2010 | USA | National insurance claims data base | 4,576 patients with chronic HBV without known cirrhosis | 6.7% had complete surveillance (one ultrasound every 6 months) |
Tran et al.196 | 2007–2014 | USA | National insurance claims data base | 55,317 patients with chronic HBV infection (14.8% without known cirrhosis) | 36.5% of patients without cirrhosis received at least annual surveillance |
Nguyen et al.22 | 2013–2018 | USA | National administrative claims data base | 6,831 patients with chronic HBV without known cirrhosis | 39.3% and 51.3% received any abdominal imaging after 6 months or 12 months, respectively |
